Iovance Biotherapeutics, Inc.

NasdaqGM:IOVA Stock Report

Market Cap: US$2.5b

Iovance Biotherapeutics Future Growth

Future criteria checks 5/6

Iovance Biotherapeutics is forecast to grow earnings and revenue by 67.1% and 45.3% per annum respectively. EPS is expected to grow by 66.2% per annum. Return on equity is forecast to be -27.7% in 3 years.

Key information

67.1%

Earnings growth rate

66.2%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate45.3%
Future return on equity-27.7%
Analyst coverage

Good

Last updated11 Nov 2024

Recent future growth updates

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11
Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Recent updates

Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity

Nov 11

Iovance Biotherapeutics: Moving To The Next Phase

Oct 03

Iovance Therapeutics: Historic Product, Tough Commercial Outlook

Sep 06

Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Aug 11
Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates

Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Aug 11

Iovance Biotherapeutics: Amtagvi Launch Continues Upward

Jun 26

Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi

May 10

Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results

Apr 09

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

Mar 25

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

Feb 20

Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date

Jan 19

Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates

Sep 27

Iovance submits rolling license application to FDA for skin cancer treatment lifileucel

Aug 25

Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Aug 25
Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss

Aug 04

Iovance: TIL Cell Therapy Set To Prove Itself

Jul 11

Iovance: Onward To Approval

Apr 20

Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside

Mar 25

Earnings and Revenue Growth Forecasts

NasdaqGM:IOVA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026739-59539210
12/31/2025460-249-155-15813
12/31/2024162-361-280-23813
9/30/202491-410-374-364N/A
6/30/202433-440-400-389N/A
3/31/20242-450-405-384N/A
12/31/20231-444-384-362N/A
9/30/20231-433-377-356N/A
6/30/20230-419-355-335N/A
3/31/2023N/A-412-333-319N/A
12/31/2022N/A-396-313-293N/A
9/30/2022N/A-390-294-269N/A
6/30/2022N/A-376-296-263N/A
3/31/2022N/A-358-278-239N/A
12/31/2021N/A-342-266-228N/A
9/30/2021N/A-311-290-237N/A
6/30/2021N/A-284-281-220N/A
3/31/2021N/A-265-259-202N/A
12/31/2020N/A-260-252-205N/A
9/30/2020N/A-255-223-196N/A
6/30/2020N/A-246-208-198N/A
3/31/2020N/A-230-202-195N/A
12/31/2019N/A-198-166-159N/A
9/30/2019N/A-167-140-137N/A
6/30/2019N/A-151-125-122N/A
3/31/2019N/A-134-114-112N/A
12/31/2018N/A-124-102-101N/A
9/30/2018N/A-117-92-91N/A
6/30/2018N/A-105N/A-84N/A
3/31/2018N/A-98N/A-78N/A
12/31/2017N/A-92N/A-79N/A
9/30/2017N/A-82N/A-70N/A
6/30/2017N/A-128N/A-61N/A
3/31/2017N/A-116N/A-47N/A
12/31/2016N/A-102N/A-33N/A
9/30/2016N/A-95N/A-27N/A
6/30/2016N/A-34N/A-19N/A
3/31/2016N/A-29N/A-19N/A
12/31/2015N/A-28N/A-18N/A
9/30/2015N/A-24N/A-15N/A
6/30/2015N/A-19N/A-13N/A
3/31/2015N/A-15N/A-10N/A
12/31/2014N/A-12N/A-9N/A
9/30/2014N/A-27N/A-8N/A
6/30/2014N/A-34N/A-6N/A
3/31/2014N/A-35N/A-6N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IOVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: IOVA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IOVA is expected to become profitable in the next 3 years.

Revenue vs Market: IOVA's revenue (45.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: IOVA's revenue (45.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IOVA is forecast to be unprofitable in 3 years.


Discover growth companies